Abstract
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
Original language | English |
---|---|
Pages (from-to) | 172-178 |
Number of pages | 7 |
Journal | Breast |
Volume | 65 |
DOIs | |
State | Published - Oct 2022 |
Bibliographical note
Funding Information:This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare , Republic of Korea (grant number: HI17C2206 ) and the National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HA22C0012 ).
Publisher Copyright:
© 2022 The Authors
Keywords
- Clinical trial
- HER2 positive
- Metastatic breast cancer
- Trastuzumab biosimilar
- ctDNA